Ann: Quarterly update and Appendix 4C, page-23

They can't keep going like this for much longer. The cash will last them only another 8 or 9 months. Without business progress and having this massive cash burn rate, they will be out of jobs pretty soon. If they can't make it happen, then the business should be sold as soon as possible, into more capable hands. The pandemic should have accelerated this business, but instead they loaded the business up with costs while grinding the business progress of the mainline products to a halt. There is no excuse for this.

If the upcoming, and obviously delayed quarterly report doesn't shown top line and cash burn rate improvement, the business as it is currently run is going to be dead. I wouldn't think they can raise more money from investors. I have chipped in twice on good faith. Pre-pandemic they were rather frugal with money while making sound product development progress. Now their STD product hasn't shown progress with TGA, and existing approved products are not clearing the key FDA hurdles. 3 years of spending big and showing no results, that's not the way to win me over for a third capital raising.

It shouldn't have come to the state that it is in today.